Slide 1 Patient Reported Outcomes in Oncology Trials Virginia Kwitkowski Clinical Reviewer-- FDA Division of Drug Oncology Products Member OND Patient Reported Outcomes Committee…

Slide 1 1 Research Study: The Participation of Pregnant Women in Clinical Research: Implications for Practice within the U.S. Pharmaceutical Industry University of North…

Slide 1 The Abbreviated Donor Questionnaire Update from AABB Donor History Task Force to BPAC March 2005 Debra Kessler RN, MS Task Force Chair Slide 2 2 Donor History Questionnaire…

Slide 1 Optimizing Group Sequential Designs that Allow Changes to the Population Sampled Based on Interim Data Michael Rosenblum Department of Biostatistics Johns Hopkins…

(Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, [email protected] Genotoxic impurities Impurities are unwanted chemicals, have no therapeutic value and are…

Out of Specification Results (OOS) A One Day Workshop Presented by: Karen S. Ginsbury PCI Pharmaceutical Consulting Israel Ltd. For IFF March 2007 Purpose of Workshop Understand…

T. cruzi Incidence Study in Blood Donors and its Implications for One-time Testing of Blood Donors Robert Duncan, Ph.D. DETTD, CBER, FDA Blood Products Advisory Committee…

(Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, [email protected] Genotoxic impurities Impurities are unwanted chemicals, have no therapeutic value and are…

PowerPoint Presentation 1 Panel: Governance at the Institutional and National Levels: national regulatory frameworks Barbara J. Evans, Ph.D., J.D., LL.M. Director, Center…

PRESENTATION CPTR Overview CPTR 2012 Workshop October 2-4, 2012 1 The Challenge 2 Use this slide as intro for opening remarks: FDA Draft guidance for combi CPTR wasofficially…